Skip to main content
INSMED Inc logo

INSMED Inc — Investor Relations & Filings

Ticker · INSM ISIN · US4576693075 LEI · 529900Q55QAG41CCAC11 US Manufacturing
Open in API
Filings indexed 1,323 across all filing types
Latest filing 2017-11-08 Regulatory Filings
Country US United States of America
Listing US INSM

About INSMED Inc

https://insmed.com/

Insmed Incorporated is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's primary focus is on addressing areas of high unmet medical need. Its marketed product, Arikayce (liposomal amikacin for inhalation), is a treatment for Mycobacterium avium complex (MAC) lung disease. Insmed leverages proprietary technologies, such as its advanced liposomal pulmonary delivery system, to create novel treatments. The company maintains a diverse pipeline of investigational medicines and is actively advancing potential new therapies through various stages of clinical trials.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings
2017-11-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 2, 2017, by Insmed Incorporated. It reports the issuance of a press release regarding financial results for the three and nine months ended September 30, 2017. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The text explicitly states that the information is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition), which typically corresponds to an Earnings Release or similar announcement. Given the length of the document (3605 characters) and the nature of the content (a current report announcing financial results), this fits the definition of an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2017-11-02 English
10-Q
Interim / Quarterly Report 9M 2017
2017-11-02 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 11, 2017. It reports the closing of a public offering of common stock by Insmed Incorporated. The key content is a press release about the completion of a financing event (public offering of shares). There are no financial statements or detailed financial results included, only a disclosure of a capital raising event. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising or capital structure changes. The document length is 3620 characters, which is relatively short but contains substantive information about the financing event, not just an announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2017-09-11 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated September 5, 2017, reporting an underwriting agreement for the sale of common stock shares by Insmed Incorporated. It details the terms of the offering, the parties involved, and includes exhibits such as the underwriting agreement and legal opinions. The content focuses on a capital raising event and financing activity, not on financial results, management changes, or other report types. The length is 6654 characters, which is sufficient to contain substantive information about the financing event itself, not just an announcement. Therefore, this document fits the category of Capital/Financing Update (CAP).
2017-09-11 English
PRIMARY DOCUMENT
Director's Dealing
2017-09-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.